Atom Investors LP Purchases New Position in KalVista Pharmaceuticals, Inc. $KALV

Atom Investors LP purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 276,113 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,459,000.

Other hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets raised its position in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $55,000. Truvestments Capital LLC raised its holdings in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the period. Tower Research Capital LLC TRC raised its holdings in KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after buying an additional 7,180 shares during the period. Finally, Savant Capital LLC acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $141,000.

Insiders Place Their Bets

In related news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the firm’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total value of $2,960,232.75. Following the completion of the transaction, the insider directly owned 5,129,340 shares of the company’s stock, valued at approximately $86,942,313. This trade represents a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 10,926 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $292,598.28. Following the completion of the transaction, the chief executive officer directly owned 479,989 shares of the company’s stock, valued at $12,854,105.42. This represents a 2.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 254,602 shares of company stock valued at $4,656,670 in the last ninety days. 4.30% of the stock is currently owned by insiders.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $27.00 on Wednesday. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $27.00. The company has a market capitalization of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The firm’s 50 day moving average is $24.44 and its 200-day moving average is $19.02.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. Equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KALV has been the topic of several research analyst reports. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Stifel Nicolaus raised their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of KalVista Pharmaceuticals to a “hold” rating in a report on Saturday. Finally, JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $30.60.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.